source
- Scholar Rock receives FDA approval for apitegromab (Isembyld) to treat spinal muscular atrophyScholar Rock announced FDA approval for its injectable drug apitegromab, marketed as Isembyld, for treating spinal muscular atrophy, a rare muscle-wasting condition. The approval follows earlier s…
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…